Gilead Q4 Wins, Biktarvy Strength Bolster GILD Now

Introduction

Gilead Sciences (NASDAQ: GILD) closed the books on 2025 with results that reinforce its position as a cash-generating leader in antivirals while signaling growing momentum in oncology and liver disease. Recent weekly trading drifted lower amid broad market softness, but the company’s core commercial performance and forward guidance offer concrete drivers for investors watching HIV, hepatitis, and oncology franchises.

Q4 and Full-Year 2025: The Numbers That Matter

Gilead reported solid fourth-quarter and full-year revenue, driven largely by its HIV portfolio. Full-year sales were up modestly year-over-year, and non-GAAP earnings per share improved materially—reflecting better operational leverage and pipeline-related investments beginning to pay off.

HIV and Core Therapeutics

HIV products remain the backbone of Gilead’s top line. Biktarvy continued to deliver strong sales, capturing a dominant share of U.S. treatment volumes, while Descovy grew at a healthy clip. Gilead’s long-acting prevention option, Yeztugo (lenacapavir), is still in early commercialization but posted sequential growth and adds an important strategic dimension to the HIV franchise.

Headwinds: Veklury and Policy Changes

Not all categories were positive. Sales of Veklury (remdesivir) contracted substantially as COVID-related demand normalized, creating a notable year-over-year drag. Separately, recent Medicare Part D redesign produced a sizable, near-term revenue headwind for Gilead’s HIV business—management quantified the policy impact in the high hundreds of millions. These two items together explain a meaningful portion of the company’s headline pressure despite underlying demand.

Oncology and Liver Disease: Emerging Growth Engines

Gilead’s portfolio diversification is evident in oncology and liver disease performance. Trodelvy’s oncology revenues advanced, supporting management’s thesis that the company can expand beyond legacy antiviral strengths into oncology therapeutics. Liver disease products likewise posted growth, contributing incremental upside to recurring revenues.

Commercial Traction and Regulatory Catalysts

Trodelvy’s uptake and ongoing regulatory filings (including potential label expansions) are important catalysts to watch in 2026. Early adoption in new indications can materially expand addressable markets and lift oncology revenue over the next several quarters.

Guidance and Market Reaction

For 2026, Gilead issued guidance that implies modest revenue growth and continued strong non-GAAP EPS, signaling management confidence in execution despite near-term policy and COVID-related pressures. Share price movement in the past week—small declines versus recent highs—appears tied to broader market risk-off sentiment rather than unexpected company-specific deterioration.

Stock Context

Gilead has traded in a narrow range around the low-to-mid $150s recently, after reaching a 52-week high earlier in February. The pullback was modest and correlates with general equity weakness rather than a new negative development from Gilead itself.

Investor Takeaways

• Durable HIV cash flow: Biktarvy and Descovy continue to generate predictable revenue and margins—an anchor for valuation.
• Offsetting trends: Veklury’s decline and Medicare Part D headwinds are real but largely quantified by management, making near-term earnings impact more transparent.
• Oncology upside: Trodelvy and other oncology assets are the primary sources of upside versus street expectations, with regulatory milestones likely to move sentiment.
• Early-stage growth plays: Long‑acting HIV prevention (Yeztugo) and liver therapies provide optionality for sustained growth beyond the core antiviral business.

Conclusion

Gilead’s most recent quarter underscored a transition: strong, reliable returns from established antivirals combined with emerging contributions from oncology and liver disease. Short-term headwinds—most notably from COVID antiviral normalization and Medicare policy changes—are offset by robust HIV sales and a clearer path to new growth drivers. For investors focused on biotech companies with stable cash flow and credible runway for therapeutic diversification, Gilead presents a case of measured resilience and tangible catalysts through 2026.